Synonymer & Information om | Engelska ordet GRAFT-VERSUS-HOST

Exempel på hur man kan använda GRAFT-VERSUS-HOST i en mening

• Additionally, it is used for treating graft-versus-host disease after a bone marrow transplant, or for the treatment of auto-immune diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, or Crohn's disease.
• PUVA (psoralen and UVA) is an ultraviolet light therapy treatment for skin diseases: vitiligo, eczema, psoriasis, graft-versus-host disease, mycosis fungoides, large plaque parapsoriasis, and cutaneous T-cell lymphoma, using the sensitizing effects of the drug psoralen.
• Other causative agents include the Epstein-Barr virus, cytomegalovirus, group A streptococcus, and non-infectious conditions such as graft-versus-host disease.
• Zolimomab aritox is a mouse monoclonal antibody which has been investigated for the treatment of systemic lupus erythematosus and graft-versus-host disease, but the studies failed to show positive effects of the drug.
• In selected human malignancies such as acute myeloid leukemia, allogeneic hematopoietic cell transplantations have shown that the development of donor NK cells in recipient patients lacking donor KIR ligands can lead to improved engraftment and post-transplant survival by boosting graft-versus-leukemia effect in the absence of graft-versus-host disease.
• Maraviroc appears to reduce graft-versus-host disease in people treated with allogeneic bone marrow transplantation for leukemia, in a Phase I/II study.
• The donor's CD8+ T cell targets the recipient’s nucleated cell resulting in graft-versus-host disease.
• Complications of DLI include acute and chronic graft-versus-host disease and bone marrow aplasia, resulting in immunosuppression and susceptibility to opportunistic infections.
• Scientists at Hanyang University in Seoul showed that tetravalent CTLA4-Ig and tetravalent LAG3-Ig could synergistically prevent acute graft-versus-host disease in animal models.
• Other causes of ductopenia include failing liver transplant, Hodgkin's lymphoma, graft-versus-host disease (GVHD), sarcoid, cytomegalovirus infection, HIV, and medication toxicity, such as phenothiazines.
• There are two types of stem cell (bone marrow) transplants: autologous stem cell transplant, where the person's own stem cells are collected, frozen, and stored before the chemotherapy regimen and transfused back into their body by IV after chemotherapy, and allogeneic stem cell transplant, where the stem cells come from a donor that matches the person's HLA type to prevent the risk of graft-versus-host disease.
• It is closely linked with graft-versus-host disease (GvHD), as the underlying principle of alloimmunity is the same.
• Practices of microtransplantation has shown none graft-versus-host disease (GVHD) till present, thus immunosuppressive drugs for relieving GVHD wouldn't be necessary.
• squamous cell carcinoma of head and neck, gestational trophoblastic disease, acute leukaemias, non-Hodgkin lymphoma, osteosarcoma, brain tumours, graft-versus-host disease and systemic sclerosis.
• It has entered clinical trials for acute myeloid leukaemia (AML), chronic lymphocytic leukemia (CLL), diffuse large B cell lymphoma (DLBCL), graft-versus-host disease (GvHD), hematological malignancies, mantle cell lymphoma (MCL), and non-Hodgkin lymphoma (NHL).
• Besides, it has been shown that the adoptive transfer of alloreactive NK cells does not cause graft-versus-host disease (GVHD), but instead suppresses GVHD.
• Belumosudil is indicated for the treatment of people aged twelve years and older with chronic graft-versus-host disease (chronic GVHD) after failure of at least two prior lines of systemic therapy.
• Herman Waldmann, Slavin was the first to introduce the use of an anti-CD52 monoclonal antibody (CAMPATH-1; Alemtuzumab and currently Lemtrada) that was initially used by Slavin for prevention of graft-versus-host disease (GVHD) and subsequently by others for prevention and treatment of allograft rejection and subsequently approved by FDA for treatment of multiple sclerosis.
• She was the principal investigator of the first clinical trial using Tr1 cells that are generated ex vivo to treat graft-versus-host disease in leukemia patients receiving a haploidentical haematopoietic stem cell transplant and is the principal investigator of an additional clinical trial utilizing these cells in the United States.
• In his research, he also highlighted the significance of pathogenic T cells to produce GM-CSF, as a vital step for the initiation and maintenance of the inflammatory cascade, which leads to progressive immunopathology and irreversible tissue destruction in neuroinflammation as well as in graft-versus-host disease.

Förberedelsen av sidan tog: 404,85 ms.